Targeting WFS1 overcomes KRAS

Yixi Chen, Jingwen Zhang, Ying Miao, Jiayu Wang, Jingtong Na, Xiyu Liu, Zhengfang Yi, Huang Chen, Mingyao Liu

Abstract read

In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yixi Chen *State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development，Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning, Guangxi, China.

Jingwen Zhang *Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, P.R. China.

Ying Miao *Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, P.R. China.

Jiayu WangShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, P.R. China.

Jingtong NaState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development，Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning, Guangxi, China.

Xiyu LiuState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development，Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning, Guangxi, China.

Zhengfang YiShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, P.R. China. zfyi@bio.ecnu.edu.cn.

Huang ChenShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, P.R. China. huangchen9104@163.com.

Mingyao LiuState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development，Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning, Guangxi, China. myliu@bio.ecnu.edu.cn.

Funding

Guangxi Science and Technology Major Program No.AA24263028National Natural Science Foundation of China 82202897, 82230002, 82373146Shanghai Rising-Star Program 23QB1405600The Jointed PI Program from Shanghai Changning Maternity and Infant Health Hospital PI202430The Scientific and Technological Innovation Major Base of Guangxi No.2022-36-Z05

6 · The paper itself

Abstract

KRAS

Identifiers

PMID42298062

DOI10.1038/s41698-026-01553-4

PMCPMC13282380

What Socratic holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.